Medindia

X

Drugs Sutent and Afinitor Show Promise in Treatment of Rare Type of Pancreatic Cancer

by Savitha C Muppala on  February 11, 2011 at 1:14 PM Drug News   - G J E 4
Two kidney cancer drugs have been found to be good in the treatment of a rare type of pancreatic cancer.
 Drugs Sutent and Afinitor Show Promise in Treatment of Rare Type of Pancreatic Cancer
Drugs Sutent and Afinitor Show Promise in Treatment of Rare Type of Pancreatic Cancer
Advertisement

Recent studies conducted with drugs Sutent from Pfizer and Afinitor from Novartis have shown improvement in patients with pancreatic neuroendocrine tumors by slowing down the progression of cancer.

Advertisement
One out of three patients undergoing treatment with the drug Afinitor from Novartis, did not show any tumor growth in the 18 month period of treatment vis a vis one out 10 patients treated with a placebo.

Explaining the efficacy of this drug, David C. Metz, MD, co-director of the Neuroendocrine Tumor Center at the University of Pennsylvania Health System, said, "Most pancreatic cancer patients die pretty quickly, but patients with these tumors tend to do well for a very long time."

One needs to wait and watch if the best treatment is found from the use of a single drug , either Sutent or Afinitor or a combination of both these drugs.   



Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions
I would like to make you aware of a new website. If you are interested in neuroendocrine tumors / carcinoids a new scientific website has started that focus only on these diseases. Check. www.NETipedia.org
rogerb Friday, February 11, 2011

You May Also Like

Advertisement
View All